Mutations of isocitrate dehydrogenase 1 (IDH1 located on chromosome 2q33.3) and IDH2 (located on chromosome 15q26.1) were first described in low-grade gliomas/secondary glioblastomas with a remarkable mutational frequency of B70%.
1 IDH1 and IDH2 mutations have since been described in acute and chronic myeloid malignancies, albeit at a much lower mutational frequency:
2 approximately 1% in essential thrombocythemia (ET), 2% in polycythemia vera (PV), 1% in post-PV/ET myelofibrosis, 4% in primary myelofibrosis, 4% in myelodysplastic syndromes (MDS), 15% in acute myeloid leukemia (AML), 15% in post-MDS AML, 22% in post-MPN AML and 22% in higher-risk MDS or AML associated with isolated 5q-. [3] [4] [5] [6] [7] In AML, IDH mutations were significantly associated with normal karyotype, NPM1 mutations and isolated trisomy 8. 8 Trisomy 8 is the most common among sole cytogenetic abnormalities in both AML and MDS with respective incidences of 6 and 11%. 9 In both AML and MDS, trisomy 8 is listed under 'intermediate-risk cytogenetic group'. Little is known about the pathogenetic effect of trisomy 8 in myeloid malignancies. In the very first report published on IDH mutations in AML, 10 13 of the 16 IDH1 mutations detected were associated with normal karyotype, 2 with trisomy 8 and 1 with trisomy 13. In a subsequent study, 8 20 of 26 IDH1 mutations detected were associated with a normal karyotype, 3 with trisomy 8 and 3 with other abnormalities. Trisomy 8 was also recurrent in patients with IDH1/IDH2-mutated post-MDS AML 11 but not in their counterparts with post-MPN AML. 6 In this study we examined the prevalence and disease distribution of IDH1 and IDH2 mutations in a large (n ¼ 157) group of patients with hematologic malignancies and isolated trisomy 8.
After approval by the institutional review board, the Mayo Clinic cytogenetic database spanning the years 1988 through 2008 was queried to identify adult (ageX18 years) cases associated with isolated trisomy 8 in their bone marrow; among 22 403 unique patient cytogenetic studies, 157 (0.7%) patients with isolated trisomy 8 were identified. World Health Organization-defined 12 clinical diagnosis at first sighting of trisomy 8 as a sole chromosomal abnormality was de novo MDS in 54 patients, MPN in 32, MDS/MPN in 19, de novo AML in 15, therapy-related MDS/AML in 12, post-MDS AML in 11, post-MPN AML in 1, multiple myeloma in 3, marginal zone lymphoma in 1, diffuse large B-cell lymphoma in 1, angioimmunoblastic lymphoma in 1, T-lymphoblastic leukemia in 1, primary amyloidosis in 1, MDS with concomitant lymphoproliferative neoplasm in 2; the bone marrow was morphologically nondiagnostic in 3 patients. Of note, all the patients with lymphoid malignancies, except the two with T-lymphoblastic leukemia or angioimmunoblastic lymphoma, were previously exposed to chemotherapy, and it is possible that the trisomy 8 abnormality in such cases represented a secondary therapy-related event in an occult myeloid clone. The de novo AML and MDS subcategories are listed in Table 1 .
Archived bone marrow cell pellets were used to extract DNA for IDH1 and IDH2 mutation analysis, according to previously reported methods. 6 Eighteen IDH mutations were identified: 15 IDH2 (14 R140Q and 1 R140W) and 3 IDH1 (2 R132C and 1 R132G). Of the 18, 17 IDH mutations occurred in myeloid malignancies (Table 1 ) whereas 1 (IDH2R140W) occurred in a patient with angioimmunoblastic lymphoma who was not previously exposed to chemotherapy or radiotherapy, and in whom the IDH2 mutation disappeared after effective lymphoma chemotherapy. Among the 17 IDH-mutated myeloid malignancies, disease-specific IDH1/IDH2 mutational frequencies were as follows: 27% (3/11) for post-MDS AML, 25% (3/12) for therapyrelated MDS/AML, 15% (8/54) for de novo MDS, 13% (2/15) for de novo AML and 3% (1/32) for MPN (Table 1) . In contrast, IDH mutational frequencies were significantly lower among 64 additional patients with AML or MDS without isolated trisomy 8: 7% in de novo AML (n ¼ 28), 0% in de novo MDS (n ¼ 21), 0% in post-MDS AML (n ¼ 11) and 0% in therapy-related MDS/ AML (n ¼ 4) ( Table 1) . Table 2 provides clinical details and disease outcome for the 16 IDH-mutated AML and MDS patients with isolated trisomy 8. The numbers of informative cases with de novo AML, post-MDS AML or therapy-related MDS/AML were too small for formal statistical comparisons of survival between IDH-mutated and unmutated cases. In the 54 patients with trisomy-8-associated de novo MDS, prognosis was similar between IDH-mutated (n ¼ 8; median survival 14 months) and unmutated (n ¼ 46; median survival 16 months) patients (P ¼ 0.7). All three informative cases with post-MDS AML were antedated by high-risk MDS. Similarly, the majority of IDH-mutated cases with de novo MDS belonged to high-risk MDS disease category. However, three of the eight IDH-mutated patients with de novo MDS and two of the three with therapy-related MDS did not show excess bone marrow blasts (Table 2 ). Subsequent leukemic transformation was documented in three of the eight de novo MDS patients with IDH mutations (Table 2) . One IDHmutated patient with therapy-related MDS (refractory anemia with excess of blasts-2) achieved complete remission with induction chemotherapy and remains alive after 60 months of follow-up.
This study suggests a possible association between IDH mutations and trisomy 8 in AML and MDS but not in MPN or MDS/MPN; IDH mutational frequencies in trisomy-8-associated AML and MDS (13-27%) were substantially higher than those of trisomy-8-associated MPN (3%) or MDS/MPN (0%) and also a control group with AML or MDS without isolated trisomy 8 (0-7%). The fact that the mere presence of trisomy 8 did not result in a more than expected incidence of IDH mutations in MPN or MDS/MPN makes it unlikely that such an association, if existed, would be secondary to trisomy-8-associated genetic or biologic changes. Instead, it is possible that IDH mutations, which have been shown to cluster with high-risk disease in both MPN 6 and MDS associated with 5q-, 5,13 promote a selective advantage for the survival of the clone that harbors trisomy 8. Consistent with this contention, we were able to demonstrate in one of our patients with relapsed AML the presence of IDHR132C both at initial AML diagnosis and the time of relapse, whereas the trisomy 8 abnormality was observed only at Letters to the Editor the time of relapse (Table 2) . Regardless, the presence of molecular heterogeneity among patients with trisomy-8-associated AML or MDS might explain the controversial prognostic influence of the specific cytogenetic abnormality. Finally, we show, for the first time, the occurrence of an IDH2 mutation in lymphoma and its disappearance with effective therapy; more studies are needed to validate our observation and clarify the pathogenetic or prognostic relevance of such an event. The clinical course of chronic lymphocytic leukemia (CLL) is variable and depends on disease stage, prognostic factors, age and comorbidity. 1, 2 Complete remission (CR) or partial remissions are initially obtained in most fit patients treated with combinations of fludarabine (F), cyclophosphamide (C) and rituximab (R) (FC or FCR). 3 Unfortunately, all patients will eventually relapse. There is an unmet need for biological predictors of individual drug response to facilitate correct treatment decisions early on. So far, gene expression profiling (GEP) in vivo in CLL was mainly used in a cross-sectional approach by studying patient samples before treatment. 4 We applied a sequential GEP (sGEP) approach to investigate the gene expression signature of CD19 þ selected CLL cells before and after treatment in vivo. This was complemented by protein analysis as well as by functional in vitro analysis of selected targets. The goals of this study were to (1) define molecular signatures associated with good or poor response to treatment; (2) understand differences in gene expression profiles after treatment with rituximab with FC or FC alone; (3) define changes in expression signatures shortly after treatment in responding and resistant CLL cases; (4) identify novel targets to overcome resistance. A number of genes that were up-or downregulated in responding patients were identified. We also provide a list of genes that were upregulated in CLL cells in association with insufficient clinical response. This library may serve to design drug combinations or sequences of administration to avoid or overcome resistance. A total of 20 patients with CLL diagnosed by standard criteria were enrolled in this study between 2004 and 2007. Eight patients were recruited within the CLL-8 study of German CLL Study Group. Sixteen patients received first-line and four second-line treatment. All patients were in Binet stage B (N ¼ 10) or C (N ¼ 10). Characteristics of all study patients are given briefly in Table 1 and Supplementary Table 1 . Treatment was planned for six cycles with a 28-day interval according to standard FC or FCR protocols. 2, 3 Peripheral blood samples were collected during the first cycle of therapy immediately before treatment, 1 day after rituximab administration and 1 day after FC (FCR group) or 1 day after FC (FC group). The study protocol was approved by the local ethics committee (no. 495/2003 and 11/2005). The type of clinical response after 3 months allowed classifying the patients into good responders (RE) including CR or partial response (PR) or nonresponders (NR) comprising stable disease (SD) or progressive disease (PD). Overall, 9 patients had adequate responses (9 PR) and 11 patients had inadequate responses (9 SD, 2 PD). We noted some imbalances between responders and nonresponders regarding mutational status (4 vs 8 IgVH unmutated) as well as poor-risk cytogenetics (11q deletions in 1 vs 5 cases). There were four responders in the FC and five in the FCR group with more UM patients in the FC nonresponder group compared with responders (4 UM vs 1 UM). This was less pronounced for FCR patients (4 UM in nonresponders vs 3 UM in responders) suggesting that mutational status is not always directly correlated with response.
For microarray analysis, positive selection of CD19 þ cells was performed. Although this procedure guarantees high purity and comparability for all samples, potential effects of CD19 ligation on the gene expression profile of CLL cells should still be considered. Total RNA was isolated from sorted CD19 þ cells and processed for microarray analysis using human U133A GeneChips (Affymetrix, Santa Clara, CA, USA). Complete GeneChip data sets are available online as GEO entry GSE15490 http://www.ncbi.nlm.nih.gov/projects/geo/query/acc. cgi?acc ¼ GSE15490 Microarray data were filtered with an interquartile range filter. The whole data set was processed with Bioconductor (www.bioconductor.org), based on the open source platform R (www.r-project.org). Several genes related to the effect of FC and/or FCR were identified using the statistical package limma and unsupervised clustering strategy. Hierarchical clustering was performed using Pearson's correlation coefficient as distance measure and Ward's optimization criterion to cluster genes and samples. Pathway analysis was performed using DAVID bioinformatic resources (http://david.abcc.ncifcrf.gov).
To identify statistically significant changes in gene expression, we applied a widely used linear model for the assessment of differential expression. A limited number of genes showed significant changes at this early time point after treatment. These data are in accordance with the recently published report on the changes in gene expression after fludarabine therapy. 5 Because our major goal was to find an overall signature of responders and/or nonresponders, we adopted a heuristic strategy to be able to discriminate between these two groups. We first considered the genes that were 41.5-or o1.5-fold up-or downregulated in at least 60% of the responders and nonresponders after treatment. This analysis retrieved sets of genes that were up-or downregulated in the nonresponders. This includes 101 genes that have changed after FC (including PHPT1, MDM2, BAX and FDXR), 52 genes after rituximab (including S100A8, KRAS, inositol 1,4,5-trisphosphate 3-kinase (ITPKB) and CDC42) and 29 genes after FCR (including S100A8, RHOB, JUN and GPR18) (data not shown). Of note, theses genes were not always up-or downregulated in the opposite direction between the two groups. This set of genes reflects effects of therapy, but may not necessarily predict clinical response. Therefore, we next performed a more stringent analysis by considering only genes that were up-or downregulated after treatment in 460% of nonresponders and always reversibly changed in the responders. Cutoff levels of 41.14-and o0.88-fold change allowed retrieving a reasonable number of genes that could be further evaluated for their biological significance by pathway analysis. Three gene sets were identified and appeared to best discriminate between nonresponders and responders to FC, FCR or rituximab (Supplementary Tables 2,3 and 4) . To be further able Figure 1 . LOC728913  TAF1  UBE2B  TRIM33  SLC16A6  RIPK5  LGR6  LSS  DPR1  LYPLAL1  RBM15  LOC283788  ING1  ITPKB  RBM12B  DDX17  CD44  CD44  LOC641298  NCOA5  FAM108B1  LRRFIP1  SLC2A3  NDOR1  BCL6  DCUN1D1  ITGAV  COX17  FLJ35776  CFL2  IGJ  CFL2  TMEM64  ZNF252  LOC145474  PRKY  EGR1  KLRC4  TDRKH  COPA  CTLA4  CTLA4  NUP62  IFI6  PPY2 RRP15  APRIN  HBD  ZNF518  KIAA1333  KLHL2  IL6ST  FHL1  ZNF92  HBA2  HBA2  ZHX1  NDUFA5  CENTD1  GABRB2  GABARAPL1  NDE1  CEACAM1  GM2A  GM2A  WARS  HMGB2  CLU  APOBEC3G  C21orf96   NR1D2  EFHC1  EPM2AIP1  LUC7L  GALC  CPEB4  EFHC1  ABCA1  FBXO3  ITGA4  ATM  TBRG1  GBP5  ZNF92  ARID4A  FBXO9  ASXL2  KLHL2  LOC344405  C1orf96  MRPL39  DUSP1  SFRS15  STK17B  ALS2CR13  PPIL4  CLIP1  LOC642333  KLHL24  BACH1  PTPRC  PMAIP1  ZBTB10  MYO9B  KLF8  ZNF614  EDA  TUBG1  HIG2 Table 1. to judge the quality of our gene set analysis, a Monte-Carlo strategy was applied. For each of the three gene sets, the correlation within the responders and nonresponders was calculated. Here, the correlation can be regarded as a measure for a consistent effect of these genes in relation to the response of the patients. One million gene sets of the same size were selected randomly and the corresponding correlation was calculated. This represents a kind of null distribution for the correlation coefficient. In at least 95% of all random samples, our gene sets performed better indicating that our gene sets are sensibly selected.
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In the FC group, microarray analysis detected increased expression of 24 genes and a decrease in 21 genes in the nonresponders, which were reversibly regulated in the responders (Figure 1a; Supplementary Table 2 ). These included increased expression of ITPKB, CD44, LOC641298 (PI3-kinase (PI3-K)-related SMG1), TAF1 and BCL6 in at least four of six nonresponders, 24 h after initiation of therapy. Conversely, a decrease in CTLA4 (immune response gene) and IFI6 (apoptosis related gene) was found in at least four of six patients. In the FCR group, the effect of rituximab alone was evaluated by analyzing the changes in gene expression 24 h after initiation of therapy (before administration of FC). As shown in Figure 1b and Supplementary Table 3 , changes included upregulation of CENTD1 (Centaurin delta1: GTPase and PI3-K signaling), IL6ST (immune response, antiapoptotic, PI3-K signaling) and APRIN as well as downregulation of NDE1, CLU (clusterine), GM2A, CEACAM1 and APOBEC3G in at least four of five nonresponders. Pathway analysis revealed the involvement of the phosphatidylinositol signaling system, Toll-like receptor, B-and T-cell receptor signaling, and actin cytoskeleton regulation in response to rituximab. In this group, significant changes were also found in gene expression in the samples collected at 48 h (after the first FC infusion) compared to pre-therapy levels ( Figure 1c; Supplementary Table 4 ). These included upregulation of ITGA4 (VLA-4, CD49d), ATM (ataxia telangiectasia mutated), TBRG1, GBP5, PMAIP1, EFHC1 and PTPRC in at least four of five nonresponders. Four genes (TUBG1, HIG2, EDA and KIAA1833) were upregulated upon therapy in responders. These very early changes in gene expression during the first cycle of therapy, although small in magnitude, may help in understanding the molecular events that influence the response or resistance to treatment in CLL.
To get further insight into the mechanisms leading to the beneficial effect of therapy, we focused our validation experiments on CD20 expression as immediate target of rituximab as well as the potent prosurvival pathway (PI3-K) and the surface molecules CD44 and CD49d that were increased on the RNA level in association with resistance to treatment. Microarray analysis demonstrated a transient decrease in CD20 mRNA expression 1 day after rituximab infusion in 9 of 10 FCR-treated patients (mean CD20 relative mRNA intensity before treatment: 6228 ± 4397, after rituximab 4793±4024 on day 1 and 5580±4711 on day 2). This effect was not observed in the FC group. The decrease in CD20 mRNA expression was associated with a decrease in the percentage of CD20 protein expressing CD19 þ cells (from 66.1 ± 10.3 to 27.5±6.4%) as well as the mean fluorescence intensity of CD20 on the cell surface (from 216.3 ± 39.8 to 142.8 ± 44.6), These results are in agreement with recently published data. 6 Importantly, western blotting showed a change in the total amount and the phosphorylation state of CD20 protein (Figure 2a) .
The changes in expression of PI3-K-related molecules (for example, ITPKB, LOC641298 and CENTD1) prompted us to further investigate the effect of treatment on this pathway as a paradigm for signal transduction. Reverse transcription-PCR analysis showed downregulation of AKT1, which is a downstream target of PI3-K, in the FCR, but not in the FC group (Figure 2b ). This rituximab-related effect was mainly transient in vivo. A significant downregulation of Akt1 mRNA expression and protein phosphorylation was also detected after exposure of CLL primary cells to rituximab in vitro (Figure 2c ). This suggests a mechanism of action in which engagement of rituximab with the surface molecule CD20 downregulates the prosurvival PI3-K pathway. These findings are substantiated by reported effects of rituximab on PI3-K in B-NHL cell lines. 7 Microarray analysis also revealed increased expression of CD44 (four of six nonresponders) and of CD49d/ITGA4 (four of five nonresponders) after FC and FCR, respectively (Figures 1a  and c) . These data could be also confirmed at the protein levels as shown in Figure 1d . CD44 and CD49d have been reported to be related to aggressiveness and progression of the disease in CLL. 8, 9 Therefore, we investigated whether blocking of the function of these molecules would affect CLL cell survival. Prolonged exposure of primary cells of five CLL patients to blocking antibodies against CD44 (clone IM7) or to anti-CD49d antibody (clone PS/2) was performed in cocultures with bone marrow stromal cells to minimize spontaneous apoptosis in CLL cells.
10
Results of fluorescence-activated cell sorting analysis revealed a significant induction of apoptosis in CLL cells by anti-CD44 and anti-CD49d monoclonal antibodies particularly after 5 days of incubation (Po 0.05 and 0.01 respectively; Figure 2d ). The proapoptotic effect of anti-CD49d was more pronounced compared to anti-CD44. Accordingly, CD44 and CD49d may represent additional therapeutic targets in therapy-resistant CLL cases.
Taken together, this study, although on a relatively small cohort of CLL cases, represents 'proof of principle' and shows the feasibility of linking clinical outcome to sGEP of CLL cells obtained early during treatment with the current standard regimens FC and FCR. One shortcoming of the study is that changes in GEP were subtle and not as strong as usually considered significant. This may be due to the short intervals of analysis (24-48 h) as has been also recently reported. 5 Although changes were not always statistically significant, they led to the discovery of biologically important genes and pathways and were confirmed by protein expression analysis. Importantly, we were able to validate functionally genes like CD49d, CD44, CD20 and Akt, which are closely related to the pathology of CLL. [6] [7] [8] [9] However, consolidation studies on a larger number of patients are needed and ongoing.
The sequential assessment of GEP supported with protein expression before and after therapy could reflect functional changes in CLL cells as a response to treatment. sGEP thus represents a tool to guide therapy early during the first cycle of treatment in CLL. The study revealed the involvement of genes related to PI3-K signaling (for example, ITPKB, CENTD1) and cell adhesion (CD44 and CD49d) in resistance to therapy. The PI3-K/Akt pathway was shown to be regulated downstream of CD20 signaling. Furthermore, our data confirm that CD20 is transiently downregulated after rituximab therapy and showed its regulation at the protein level and post-translational level by de-phosphorylation. This finding may have consequences on scheduling of CD20 antibody therapy. Finally, we provide a set of genes that can help to predict response or resistance to therapy and identify potential targets to overcome resistance. Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), a heterogeneous group of lymphocytic neoplasms affecting the skin. Early disease is characterized by skin patches or plaques that are based mostly on infiltrates of reactive inflammatory cells with rare malignant T cells present in the affected areas. In advanced-stage disease, that is tumor stages, however, the malignant clone expands and predominates the skin lesion; moreover, it can spread to lymph nodes, blood and eventually viscera. 1 MF is considered an incurable condition, however, due to its indolent nature, early-stage disease can be controlled for years by skin-directed therapies, such as topical corticosteroids, narrow band ultraviolet B or ultraviolet A in combination with psoralen (PUVA), and nitrogen mustard. If the disease becomes refractory to these measures, retinoids/rexinoids, interferon a, histone deacetylase (HDAC) inhibitors and low-dose chemotherapy can be used alone or in combination. Side effects accompanying these therapies range from drug hypersensitivity to increase in the risk of infection or secondary cancer, hematologic toxicity and myelosuppression. Treatment of advanced disease is problematic and often requires aggressive chemotherapy, irradiation or multiple target approaches with responses that are typically not durable; thus, the patients have a poor prognosis. Accordingly, there is a great need to develop novel targeted therapies and combination therapy for the treatment of refractory and advanced MF. 2 The etiology of MF is largely unknown, but numerous signaling pathways have been demonstrated to be involved in disease development and progression. A pathological dysregulation of the janus kinase (Jak)/signal transducer and activators of transcription (Stat) signaling axis has been detected in the majority of patients as well as a constitutive activation of other transcription factors such as NF-kB, c-Fos, c-Jun or c-Myc. Abnormal expression of cytokines interleukin (IL)-5, IL-6, IL-7, and IL-13 and angiogenetic factors is also a characteristic feature of MF.
3,1 Recently, we discovered that cyclooxygenase-2 (COX-2) is aberrantly expressed in situ in advanced MF. Importantly, the aberrant COX-2 expression is associated with disease progression suggesting a role in the malignant transformation. 4 In normal cells, COX-2 is an inducible key factor in prostaglandin synthesis and mediates inflammation by increased levels of prostaglandin. Ectopic expression of COX-2 and its downstream partner microsomal prostaglandin E synthase-1 (mPGES1) has been implicated in the pathogenesis of several cancer types, and the resulting production of prostaglandin E 2 (PGE 2 ) is known to sustain cancer progression by promotion of angiogenesis, invasion and metastasis. 5, 6 In advanced MF, the aberrant COX-2 drives a spontaneous, high production of PGE 2 . In this respect it is important to note that PGE 2 functions as growth factor for malignant T cells, and inhibitors of COX-2 and mPGES1 strongly inhibit PGE 2 -mediated proliferation of malignant T cells. 4 In particular, a COX-2 inhibitor already in clinical use for inflammatory diseases, celecoxib (Celebra, Pfizer, Ballerup, Denmark), is a highly potent inhibitor of the spontaneous proliferation of malignant T cells in vitro. 4 This study was undertaken to determine if celecoxib has the potential to inhibit tumor formation and growth also in vivo. To this end, we took advantage of a xeno-transplant mouse model of advanced MF. 7 Accordingly, COX-2-positive MyLa cells were inoculated subcutaneously into immune-deficient NOD. Cg-PrkdcscidB2mtm1Unc/J (NOD/SCID-B2m À/À ) mice (The Jackson Laboratory, Bar Harbor, ME, USA). This mouse strain is deficient for major histocompatibility complex class I, B and T cells, as well as C-5, and has low natural killer cell activity. In 80-90% of the mice, tumor formation is detected on average 14 days after inoculation. 7 In the first series of experiments, we evaluated the effect of celecoxib on implantation of MF cells. Accordingly, we initiated a 'prevention' study (Study 1) using 20 animals that were inoculated with 1 Â 10 6 MyLa cells into each flank. The mice were divided into two groups of 10 animals each, which were treated with daily intraperitoneal injections of 10 mg/g body weight celecoxib or vehicle (10% human serum, 10% dimethylsulfoxide), starting from the day of tumor cell injection. After 21 days, the experiment was terminated and Figure 1 Tumor weights in celecoxib-treated group and control (Study 1). Mean tumor weight after 21 days of treatment was 39.85 mg in the celecoxib-treated group (10 animals, n tumor ¼ 10) and 120.2 mg in the control group (10 animals, n tumor ¼ 16).
n Po0.05 (t-test). Figure 2 The Kaplan-Meier plot for mycosis fungoides (MF)-bearing mice treated with celecoxib and control (Study 2). Median survival in celecoxib (9 animals) and control group (11 animals) was 47 and 32 days, respectively. Po0.0001 (log-rank test). Sections were stained with a mouse monoclonal antibody against Ki-67 (clone MIB-1, DAKO, Glostrup, Denmark), as previously described. In brief, paraffin-embedded tissue was cut in 4 mm thick sections and processed for immunohistochemical staining. Antigen retrieval by microwaving slides submerged in EDTA buffer (pH 9) was used before immunostaining of sections for Ki-67 with peroxidase-based Envision (DAKO) and sections were counterstained with light green. Magnifications (a-d): 2.5Â. a1-a3, b1-b3, c1-c3 and d1-d3 show selected areas through the tumor in a 10 Â magnification.
tumor number and load in each group was determined ( Figure 1 ). Preventive celecoxib treatment proved very effective: it not only reduced the number of tumors from 16 in the control group to 10 in the treatment group but also reduced the mean tumor weight from 120.2 to 39.85 mg in the celecoxib-treated group. The difference proved statistically significant (t-test, Po0.05). Moreover, five animals (50%) of the treated group did not develop any tumors, whereas there were only two animals (20%) in the control group, in which tumors failed to establish. These findings suggest that celecoxib inhibits establishment of tumors and/or tumor growth, suggesting that celecoxib could have a potential role in tumor prevention in analogy with the preventive role of selective and broad COX-2 inhibitors (such as aspirin) in colon cancer. Next, we addressed the question whether celecoxib is also able to inhibit growth of already established tumors, in a 'treatment' study in the same tumor model (Study 2). To this end, treatment was delayed until tumors were clearly palpable. Of a total of 24 mice that were injected with MyLa cells, 20 developed tumors and were randomly allocated for later treatment with celecoxib at 10 mg/g body weight or vehicle and subjected to daily intraperitoneal injections for 60 days or until the tumors had reached their maximal allowed size (12 mm in the largest diameter). Figure 2 depicts the Kaplan-Meier plots of the celecoxib-treated animals and the control group. On day 38 after initiation of treatment, 78% of the celecoxib-treated animals were still alive, whereas all of the control mice had to be killed, their tumors having reached the maximal size. On day 60, when the study was terminated, the tumors of 33% of the celecoxib-treated mice (three animals) had not reached the maximal size (Table 1 ). The median survival was 47 days in the celecoxib group and 32 days in the control group (log-rank test, Po0.0001), indicating that treatment with celecoxib inhibited growth of established tumors in vivo. Discontinuation of the treatment in the three mice with submaximal tumors after day 60, resulted in all three mice in the tumor growth acceleration that almost matched the growth curves in the control, never treated mice (data not shown).
As celecoxib induces cell growth arrest in vitro, we compared tissue sections of tumors from celecoxib and control mice from the intervention study with respect to expression of the proliferation marker Ki-67. Tumors from the celecoxib-treated animals exhibited significantly lower levels of proliferation as judged from weaker Ki-67 staining. In particular, the hyperproliferative zones at the tumor edge were significantly thinner in celecoxib-treated animals ( Figure 3) . Similarly, lower proliferative activity was seen in the inner zones of tumors in celecoxibtreated mice when compared with tumors from control mice (Figure 3 ). In contrast, no significant difference in the level of apoptosis was observed between celecoxib-treated and control mice (data not shown), indicating that the inhibition of tumor growth caused by celecoxib in vivo was caused rather by an inhibition of malignant T-cell proliferation than their apoptosis. This conclusion is in keeping with our observations that celecoxib primarily induces MF cell growth arrest, but not apoptosis in vitro, 4 and that MF tumors display, after discontinuation of celecoxib treatment, an accelerated growth in vivo, as mentioned above.
In summary, we show that the COX-2 inhibitor celecoxib inhibits tumor growth in vivo in an experimental xenograft mouse model of advanced MF. In fact, the effect of celecoxib appeared to be more pronounced than that of vorinostat (an HDAC inhibitor recently approved by the Food and Drug Administration for treatment of refractory CTCL) when used in the same xenotransplantation model. 2 Given an ectopic expression of COX-2 in malignant T cells in patients with advanced MF, our findings suggest that COX-2 is a novel therapeutic target in advanced MF. Because celecoxib is already approved for several non-malignant diseases and displays limited side effects, 8 this drug could provide a novel, nonaggressive option for treatment of patients with advanced MF. However, COX-2 inhibition appears to trigger growth arrest of MF cells rather than apoptosis, which may adversely affect its efficacy as a single agent. In keeping with this hypothesis, multiple signaling pathways are believed to confer to the malignant transformation in MF. Investigations are now in progress to study the interaction and efficacy of celecoxib in combination with already existing as well as experimental therapies.
